Physician profile
John J Howard
NPI 1356319354
$9,321.25
in general payments reported to CMS, 2019-2025
46 companies · $17.17 in 2025
The $17.17 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,677 · 2020: $1,688 · 2021: $2,082 · 2022: $2,127 · 2023: $1,240 · 2024: $490 · 2025: $17.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,747.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,747.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,723.02 | 2019-2024 | Otezla, Repatha, Evenity |
| Novo Nordisk INC | $931.28 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Amarin Pharma, INC. | $788.83 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $689.46 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $685.19 | 2020-2024 | Mounjaro, Jardiance, Trulicity |
| Abbvie INC. | $668.60 | 2019-2023 | |
| Horizon Therapeutics Plc | $483.66 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $361.32 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $315.84 | 2019-2023 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $253.24 | 2019-2023 | Seglentis, Livalo |
| Pfizer INC. | $251.69 | 2019-2024 | |
| Astellas Pharma US INC | $214.49 | 2019-2023 | Veozah, Myrbetriq |
| Biogen, INC. | $173.47 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $152.74 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $152.19 | 2019-2024 | Xifaxan |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Howard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.